Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis (Q51167980)

31 March 2018

title

Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis (English)

1 reference

31 March 2018

0 references

Luca Prosperini

1 reference

31 March 2018

Chiara Rosa Mancinelli

1 reference

31 March 2018

Laura De Giglio

1 reference

31 March 2018

Floriana De Angelis

1 reference

31 March 2018

Valeria Barletta

1 reference

31 March 2018

Carlo Pozzilli

1 reference

31 March 2018

publication date

2 September 2013

1 reference

31 March 2018

Multiple Sclerosis Journal

published in

1 reference

31 March 2018

volume

1 reference

31 March 2018

issue

1 reference

31 March 2018

page(s)

566-576

1 reference

31 March 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Multiple sclerosis therapeutic strategies: Start safe and effective, reassess early, and escalate if necessary

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Scoring treatment response in patients with relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Defining interferon beta response status in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Clinical prognostic factors in multiple sclerosis: a natural history review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

'Time is brain' also in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Three years of experience: the Italian registry and safety data update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Freedom from disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

The changing face of multiple sclerosis clinical trial populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Measures in the first year of therapy predict the response to interferon β in MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502399

21 January 2018

Identifiers

DOI

10.1177/1352458513502399

1 reference

31 March 2018

1 reference

31 March 2018